We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.
- Authors
Rebold, Nicholas; Morrisette, Taylor; Lagnf, Abdalhamid M; Alosaimy, Sara; Holger, Dana; Barber, Katie; Justo, Julie Ann; Antosz, Kayla; Carlson, Travis J; Frens, Jeremy J; Biagi, Mark; Kufel, Wesley D; Moore, William J; Mercuro, Nicholas; Raux, Brian R; Rybak, Michael J
- Abstract
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.
- Publication
Open Forum Infectious Diseases, 2021, Vol 8, Issue 12, p1
- ISSN
2328-8957
- Publication type
Article
- DOI
10.1093/ofid/ofab554